📢🔥Take note! Data from the massive MSBase Registry dataset shows that secondary and primary progressive MS disease differ in disease onset and course. This is super important to consider when studying disease modifying therapies. bit.ly/41i7x0w Izanne

Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks jnnp.bmj.com/content/early/… Joachim Havla

Every physician caring for patients with Guillain-Barre Syndrome (GBS) should read this recent excellent review. nature.com/articles/s4157… There are two important points that I believe are not emphasized enough in this paper: 1. We have shifted away from classifying patients as

The benefits of early initiation of disease-modifying therapy in MS are well-established, but when & how to de-escalate treatment remains unclear. Androdias et al. summarise findings from an ECTRIMS workshop on this topic and propose practical guidelines. tinyurl.com/mr2rvxcu

Happy to share our international (🇪🇸🇫🇷🇮🇹🇨🇭) collaborative study focused on the role of cytokines measured by ELLA system in MOGAD. neurology.org/doi/10.1212/NX…

*** Two doctoral scholarships available by Max Planck School of Cognition Max Planck School of Cognition and Berlin School of Mind and Brain Mind and Brain funded by DAAD *** 👉 Two topics: (1) Heart and Brain & (2) Autoimmune #encephalitis 👉 International applicants only mind-and-brain.de/doctoral-progr…

Using multivariable Mendelian randomization, Chiesa et al. show that differences in brain volumes that are commonly attributed to obesity in adults are likely to have instead arisen due to earlier obesity in childhood. tinyurl.com/5n8ss6a7

My group has an open postdoctoral position researching single cell and high dimensional flow cytometry data analysis in #MOGAD Kids Research University of Sydney ISNI-The International Society of Neuroimmunology Neuroimmunology Australia Apply here and join us: usyd.wd3.myworkdayjobs.com/USYD_EXTERNAL_…

Major academic publishers make billions of dollars. Elsevier: $3.9 billion, Springer Nature: $2 billion, Wiley: $1.8 billion As for peer reviewers, they are paid $0. ReseachHub is a new online platform that pays peer reviewers up to $150 per review:

1/2 These publications are a true testament of the hard work & collaborative efforts of so many of our colleagues from Australia & NZ. Dr Jessica Shipley (first author) & I are very grateful! So many clinicians & those with lived experiences of #MS contributed.

2 more weeks! If you can’t make it, no problem, just register here for free & hear talks from our outstanding experts recorded during after the event! mogproject.org/imps2025/ Experts include: Michael Levy, MD, PhD, Grace Gombolay, MD, Elia Sechi, Tanuja Chitnis, Benjamin Greenberg & more!

New Findings Alert Our study reveals how smoking and vascular risk factors may affect recovery in #NMOSD and #MOGAD. Grateful to my supervisors in Nuffield Department of Clinical Neurosciences and University of Sydney for this opportunity. A great souvenir from my Oxford fellowship! Introductory video below ⬇️

New research highlights a potential biomarker in pediatric MOGAD: children with non-P42 MOG epitopes were younger at onset, more likely to present with ADEM, and had higher relapse risk. Our coverage🔍 hubs.li/Q03j3fnG0

Delighted to share our recent contribution led by Magdalena Lerch⁩ to a special edition of Seminars in Immunology! We take a deep dive into the pathogenesis of neurological immune related adverse events post immune checkpoint inhibitor therapy 🧠🧪 sciencedirect.com/science/articl…

MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally sciencedirect.com/science/articl…

We’re currently looking for Australian &/or New Zealand expert #MOGAD doctors to come to our support zoom in a few months time to meet some of our wonderful ANZ MOG+ pts & answer some Qs. This has been done with both US, UK & Europe so Australia it’s now your turn! Looking to

Beware commercial tissue based assays (TBAs) to detect cell surface autoantibodies in neurology. TBAs are often used as screening tests and are reader dependent. Bottom line: please think clinically when diagnosing autoimmune neurological syndromes pubmed.ncbi.nlm.nih.gov/40393020/